KRTX - Karuna Therapeutics Inc Stock Price, Fair Value and News

329.83USD Delayed

Market Summary

USD329.83

Delayed

KRTX Stock Price

View Fullscreen

KRTX RSI Chart

KRTX Valuation

Market Cap

12.6B

Price/Earnings (Trailing)

-29.05

Price/Sales (Trailing)

247.43

EV/EBITDA

-28.78

Price/Free Cashflow

-32.41

KRTX Price/Sales (Trailing)

KRTX Profitability

EBT Margin

-850.37%

Return on Equity

-34.58%

Return on Assets

-32.46%

Free Cashflow Yield

-3.09%

KRTX Fundamentals

KRTX Revenue

Revenue (TTM)

50.9M

Rev. Growth (Yr)

336.46%

Rev. Growth (Qtr)

2.14%

KRTX Earnings

Earnings (TTM)

-433.7M

Earnings Growth (Yr)

-49.35%

Earnings Growth (Qtr)

4.45%

Breaking Down KRTX Revenue

Last 7 days

3.1%

Last 30 days

2.8%

Last 90 days

50.1%

Trailing 12 Months

74.2%

How does KRTX drawdown profile look like?

KRTX Financial Health

Current Ratio

19.31

KRTX Investor Care

Shares Dilution (1Y)

10.67%

Diluted EPS (TTM)

-11.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	21.7M	37.9M	50.9M	0
2022	30.4M	23.8M	17.2M	10.6M
2021	2.1M	1.4M	19.2M	37.0M
2020	3.5M	4.1M	4.0M	3.3M
2019	0	0	0	2.5M
2018	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Karuna Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	meury william	back to issuer	-9,695,070	330	-29,379	president and ceo
Mar 18, 2024	paul steven m	back to issuer	-3,496,680	330	-10,596	-
Mar 18, 2024	paul steven m	back to issuer	-10,000,300	330	-30,304	-
Mar 18, 2024	torres denice	back to issuer	-326,700	330	-990	-
Mar 18, 2024	healy james	back to issuer	-11,051,700	330	-33,490	-
Mar 18, 2024	paul steven m	back to issuer	-11,181,100	330	-33,882	-
Mar 18, 2024	jonas jeffrey m	back to issuer	-326,700	330	-990	-
Mar 18, 2024	healy james	back to issuer	-225,390	330	-683	-
Mar 18, 2024	healy james	back to issuer	-2,648,250	330	-8,025	-
Mar 18, 2024	paul steven m	back to issuer	-11,839,400	330	-35,877	-

Which funds bought or sold KRTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Capital Advisors, Ltd. LLC	sold off	-100	-3,000	-	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	sold off	-100	-32,311,200	-	-%
Apr 18, 2024	Park Place Capital Corp	sold off	-100	-1,266	-	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	sold off	-100	-2,773,580	-	-%
Apr 17, 2024	Clarius Group, LLC	sold off	-100	-21,917,700	-	-%
Apr 16, 2024	KRS Capital Management, LLC	sold off	-100	-748,230	-	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	sold off	-100	-145,911	-	-%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	sold off	-100	-401,335	-	-%
Apr 15, 2024	Legato Capital Management LLC	sold off	-100	-353,542	-	-%
Apr 15, 2024	JANICZEK WEALTH MANAGEMENT, LLC	sold off	-100	-1,583	-	-%

Are Funds Buying or Selling KRTX?

Are funds buying KRTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KRTX

No. of Funds

Unveiling Karuna Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	t. rowe price investment management, inc.	7.2%	2,709,629	SC 13G
Feb 14, 2024	price t rowe associates inc /md/	5.2%	1,963,957	SC 13G/A
Feb 13, 2024	vanguard group inc	8.55%	3,224,786	SC 13G/A
Feb 12, 2024	fmr llc	-	0	SC 13G/A
Feb 12, 2024	capital international investors	1.2%	448,866	SC 13G/A
Feb 09, 2024	capital international investors	11.4%	4,314,384	SC 13G/A
Jan 31, 2024	blackrock inc.	5.3%	2,015,374	SC 13G
Jan 10, 2024	fmr llc	-	0	SC 13G/A
Jul 07, 2023	blackrock inc.	4.97%	1,864,318	SC 13G/A
Jun 21, 2023	sofinnova venture partners x, l.p.	3.7%	1,372,441	SC 13D/A

Recent SEC filings of Karuna Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Mar 28, 2024	15-12G	15-12G
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	S-8 POS	Employee Benefits Plan
Mar 18, 2024	S-8 POS	Employee Benefits Plan
Mar 18, 2024	S-8 POS	Employee Benefits Plan
Mar 18, 2024	S-8 POS	Employee Benefits Plan
Mar 18, 2024	S-8 POS	Employee Benefits Plan
Mar 18, 2024	POSASR	POSASR
Mar 18, 2024	8-K	Current Report
Mar 18, 2024	4	Insider Trading

Peers (Alternatives to Karuna Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Karuna Therapeutics Inc News

Latest updates

Karuna Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q1	2018Q4
Revenue	-100.0%	-	16,952,000	16,597,000	11,345,000	6,026,000	3,884,000	490,000	394,000	298,000	202,000	106,000	143,000	441,000	688,000	779,000	1,397,000	1,092,000	858,000	115,000	-
Operating Expenses	-4.9%	129,586,000	136,218,000	119,907,000	109,720,000	90,314,000	81,075,000	70,330,000	58,594,000	65,155,000	51,168,000	34,531,000	29,963,000	24,407,000	19,529,000	17,825,000	10,055,000	8,866,000	9,896,000	11,573,000	8,146,000
S&GA Expenses	46.9%	47,394,000	32,266,000	27,417,000	24,253,000	24,310,000	19,125,000	17,843,000	14,788,000	20,063,000	12,393,000	10,384,000	9,777,000	8,823,000	6,944,000	7,006,000	5,635,000	3,874,000	4,103,000	4,606,000	1,426,000
R&D Expenses	-20.9%	82,192,000	103,952,000	92,490,000	85,467,000	66,004,000	61,950,000	52,487,000	43,806,000	45,092,000	38,775,000	24,147,000	20,186,000	15,584,000	12,585,000	10,819,000	4,420,000	4,992,000	5,793,000	6,967,000	6,720,000
EBITDA Margin	-9.6%	-8.47	-7.73	-9.29	-14.40	-25.74	-13.15	-8.43	-5.62	-3.88	-7.28	-77.99	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	890,000	-	528,000	-	6,000	-	-	-	43,000	-	-	-	-	-	-	-
Earnings Before Taxes	5.0%	-113,154,000	-119,119,000	-103,163,000	-97,574,000	-75,322,000	-76,963,000	-64,415,000	-58,218,000	-27,954,000	-50,932,000	-34,416,000	-30,497,000	-23,966,000	-18,841,000	-17,046,000	-8,658,000	-7,774,000	-9,038,000	-12,005,000	-8,327,000
EBT Margin	-9.6%	-8.50	-7.76	-9.33	-14.45	-25.85	-13.22	-8.47	-5.65	-3.89	-7.29	-78.17	-	-	-	-	-	-	-	-	-
Net Income	4.4%	-113,824,000	-119,119,000	-103,163,000	-97,574,000	-76,212,000	-76,963,000	-64,943,000	-58,218,000	-27,960,000	-50,932,000	-34,416,000	-30,497,000	-24,009,000	-18,841,000	-17,046,000	-8,658,000	-7,774,000	-9,038,000	-12,005,000	-8,327,000
Net Income Margin	-9.5%	-8.52	-7.78	-9.35	-14.52	-25.98	-13.25	-8.49	-5.65	-3.89	-7.30	-78.20	-	-	-	-	-	-	-	-	-
Free Cashflow	-1.1%	-111,839,000	-110,626,000	-64,975,000	-101,314,000	-79,047,000	-60,120,000	-39,951,000	-49,803,000	-7,767,000	-45,325,000	-29,632,000	-21,226,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-3.5%	1,336	1,385	1,472	1,516	1,163	1,228	434	474	528	540	577	593	348	364	378	390	393	164	79.00	48.00	16.00
Current Assets	-3.7%	1,315	1,365	1,452	1,508	1,155	1,220	424	465	517	529	567	590	345	361	375	387	393	164	79.00	-	16.00
Cash Equivalents	0.7%	186	184	264	563	248	628	136	176	207	252	346	354	53.00	45.00	134	191	209	54.00	10.00	-	9.00
Net PPE	15.0%	5.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Liabilities	30.6%	82.00	63.00	53.00	28.00	37.00	44.00	28.00	21.00	26.00	22.00	17.00	8.00	9.00	7.00	6.00	5.00	3.00	2.00	2.00	3.00	4.00
Current Liabilities	39.1%	68.00	49.00	39.00	25.00	34.00	41.00	24.00	16.00	20.00	16.00	10.00	7.00	7.00	5.00	4.00	3.00	3.00	2.00	2.00	-	1.00
Shareholder's Equity	-5.1%	1,254	1,322	1,420	1,488	1,126	1,184	405	454	502	518	560	585	339	357	372	385	390	163	-	-	-
Retained Earnings	-12.9%	-997	-884	-764	-661	-564	-488	-411	-346	-287	-259	-208	-174	-144	-120	-101	-84.17	-75.51	-67.74	-58.70	-	-31.55
Additional Paid-In Capital	2.1%	2,256	2,209	2,188	2,152	1,694	1,676	819	802	790	778	769	759	483	477	472	468	465	230	12.00	-	2.00
Shares Outstanding	0.9%	38.00	38.00	38.00	37.00	34.00	31.00	30.00	30.00	29.00	30.00	29.00	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	5,873	-	-	-	2,921	-	-	-	3,027	-	-	-	2,231	-	-	-	197	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-0.9%	-111	-110	-64.16	-100	-78.76	-59.95	-39.50	-49.80	-7.00	-43.81	-28.89	-21.18	-22.94	-22.78	-15.79	-8.34	-6.82	-8.42	-9.57	-6.11	-6.86
Share Based Compensation	24.6%	23.00	18.00	18.00	16.00	13.00	12.00	12.00	11.00	8.00	8.00	7.00	6.00	4.00	4.00	3.00	2.00	1.00	2.00	7.00	3.00	0.00
Cashflow From Investing	226.5%	92.00	28.00	-253	-27.49	-306	-292	-5.55	18.00	-42.02	-50.37	19.00	51.00	30.00	-66.83	-42.05	-10.43	-72.62	-42.18	-64.52	5.00	-
Cashflow From Financing	647.2%	20.00	3.00	18.00	442	5.00	844	5.00	1.00	4.00	1.00	2.00	271	2.00	1.00	1.00	1.00	234	94.00	0.00	77.00	3.00

KRTX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
License and other revenue	$ 654	$ 10,637	$ 36,964
Operating expenses:
Research and development	364,101	224,247	128,200
General and administrative	131,330	76,066	52,617
Total operating expenses	495,431	300,313	180,817
Loss from operations	(494,777)	(289,676)	(143,853)
Other income, net:
Interest income	61,179	14,178	502
Sublease income	588	580	254
Impairment loss on right-of-use assets	0	0	(702)
Total other income, net	61,767	14,758	54
Net loss before income taxes	(433,010)	(274,918)	(143,799)
Income tax provision	(670)	(1,418)	(6)
Net loss attributable to common stockholders	$ (433,680)	$ (276,336)	$ (143,805)
Net loss per share, basic	$ (11.73)	$ (8.74)	$ (4.94)
Net loss per share, diluted	$ (11.73)	$ (8.74)	$ (4.94)
Weighted average common shares outstanding used in computing net loss per share, basic	36,959,049	31,629,013	29,138,915
Weighted average common shares outstanding used in computing net loss per share, diluted	36,959,049	31,629,013	29,138,915

KRTX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 185,823	$ 248,329
Investment securities, available-for-sale	1,074,957	875,715
Short-term investments, other	2,033	0
Accounts receivable	0	57
Prepaid expenses	39,993	29,106
Other current assets	12,507	1,562
Total current assets	1,315,313	1,154,769
Restricted cash	0	261
Right-of-use lease assets - operating, net	15,090	4,674
Property and equipment, net	5,424	3,201
Other non-current assets	382	429
Total assets	1,336,209	1,163,334
Current liabilities:
Accounts payable	6,783	2,379
Accrued expenses	41,609	29,285
Current portion of operating lease liability	2,843	2,282
Other current liabilities	16,894	0
Total current liabilities	68,129	33,946
Operating lease liability, net of current portion	13,845	3,046
Other non-current liabilities	0	104
Total liabilities	81,974	37,096
Commitments and Contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and 0 shares outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value; 150,000,000 shares authorized as of December 31, 2023 and 2022; 38,091,829 and 34,473,905 shares issued as of December 31, 2023 and 2022; 38,077,525 and 34,473,905 shares outstanding as of December 31, 2023 and 2022, respectively	4	3
Additional paid-in capital	2,256,431	1,693,732
Accumulated deficit	(997,887)	(564,207)
Accumulated other comprehensive (loss) income	211	(3,290)
Treasury stock at cost, 14,304 and 0 shares as of December 31, 2023 and 2022, respectively	(4,524)	0
Total stockholders’ equity	1,254,235	1,126,238
Total liabilities and stockholders’ equity	$ 1,336,209	$ 1,163,334

About Karuna Therapeutics Inc

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

CEO	Mr. William Meury
WEBSITE	karunatx.com
INDUSTRY	Biotechnology
EMPLOYEES	210

Karuna Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Karuna Therapeutics Inc? What does KRTX stand for in stocks?

KRTX is the stock ticker symbol of Karuna Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Karuna Therapeutics Inc (KRTX)?

As of Mon Mar 18 2024, market cap of Karuna Therapeutics Inc is 12.6 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KRTX stock?

You can check KRTX's fair value in chart for subscribers.

What is the fair value of KRTX stock?

You can check KRTX's fair value in chart for subscribers. The fair value of Karuna Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Karuna Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KRTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Karuna Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether KRTX is over valued or under valued. Whether Karuna Therapeutics Inc is cheap or expensive depends on the assumptions which impact Karuna Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KRTX.

What is Karuna Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Mar 18 2024, KRTX's PE ratio (Price to Earnings) is -29.05 and Price to Sales (PS) ratio is 247.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KRTX PE ratio will change depending on the future growth rate expectations of investors.